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Abstract 
Type  IV  osteolysis  or  Gorham-Stout  syn-
drome  is  a  rare  condition  characterized  by
recurrent vascular tumors that disrupt normal
anatomical  architecture.  Gorham-Stout  syn-
drome is most commonly associated with the
skeletal system with resulting replacement of
bone with scar tissue following tumor regres-
sion.  The  loss  of  entire  bones  has  given
Gorham-Stout syndrome the moniker vanish-
ing  bone  disease.  Natural  progression  of
Gorham-Stout  syndrome  is  characterized  by
spontaneous disease resolution. However, rare
variants of recurrent, progressive, and/or sys-
temic disease have been reported. We present
a patient with a history of recurrent Gorham-
Stout  disease  refractory  to  all  treatment
options considered. In addition to skeletal dis-
ease,  our  patient  had  soft  tissue  and  cuta-
neous involvement, thus reflecting the more
aggressive disease variant. Previous surgical
attempts to control disease had been ineffec-
tive and the patient was referred to us for radi-
ation therapy. Treatment with external beam
radiation therapy resulted in good local control
and symptom palliation, but full disease reso-
lution was never accomplished. In addition to
presentation of this patient, a review of the lit-
erature  on  etiological  hypotheses  and
past/future treatment options was conducted
and is included.
Introduction
Type  IV  osteolysis  or  Gorham-Stout  syn-
drome is a rare variant of idiopathic osteolytic
disease.
1 In 1838 Jackson first described the
disease in an 18-year-old man with a gradually
vanishing  humerus.
2 Later,  in  1955  Gorham
and Stout identified and reported 16 patients
with similar disease.
3 Gorham-Stout syndrome
is characterized by progressive angiomatosis
of venous, capillary, or lymphatic origin.
4-6 The
pathology of Gorham-Stout syndrome is associ-
ated  with  angiomatosis  coupled  with  active
osteolysis resulting in vascular tumor replace-
ment of bone. The osteolysis can be monostot-
ic or polyostotic and has the potential to result
in the physical loss of entire bones – hence the
term “vanishing bone disease.” Involution and
resolution, whether spontaneous or treatment
induced,  will  result  in  replacement  of  the
lesion with connective tissue; thus changing
the underlying anatomy and physiology of the
region.  Often,  presentation  of  Gorham-Stout
syndrome is a consequence of the comprom  -
ised skeletal framework.
1,7 Anatomical malfor-
mations and pathological fractures are often
seen  as  common  symptoms  of  presentation.
Other presenting signs or symptoms are asso-
ciated with underlying inflammation, such as
fatigue and generalized pain.
7 Diagnosis is a
combination of clinical suspicion with support-
ive imaging, but is confirmed by histopatholog-
ical  analysis  of  the  lesions.  Biopsy  always
shows extensive nonmalignant hyperprolifera-
tion of small vessels.
1,5,7
Gorham-Stout Syndrome Review
Gorham-Stout syndrome has been described
in all anatomical locations and tissue types,
but is seen most commonly in the anatomical
girdles  (pelvic  or  shoulder)  or  in  the  long
bones of the extremities. Rarely, soft tissue or
skin  lesions  are  seen  and  their  presence
reflects an increased severity of disease. One
review noted that only five of the 220 (2.27%)
reported cases of Gorham-Stout syndrome had
cutaneous involvement in their disease.
5When
present,  soft  tissue  lesions  are  reflective  of
involved bone distribution.
5
Patient age ranges have been reported from
one  month  to  75  years,
1 with  children  and
young adults being most commonly afflicted.
To date, there has not been an epidemiologic
correlation with race, gender, or geography.
7-10
Originally, Gorham and Stout postulated the
tumors to be secondary to progressive hem  -
angiomatosis.
3,10 The  etiology  is  largely
unknown but is thought to be multifactorial.
Review of current literature yielded many pos-
sible etiological factors. In summary, Gorham-
Stout  syndrome  is  thought  to  result  from  a
complex  interaction  between  growth  factors,
angiogenic factors, and inflammatory media-
tors.  A  previous  study  identified  histological
markers on the characteristic cells of Gorham-
Stout syndrome that indicate a monocyte line-
age.
11 These so-called Gorham cells (GCs) have
been shown to respond to known osteoclastic
and  angiogenic  factors  resulting  in  disease
specific  pathology.  In  particular,  vascular
endothelial  growth  factor  (VEGF)  subtypes,
platelet-derived  growth  factor  subtypes
(PDGF), and inflammatory cytokines (TGF, IL-
6, and IL-1) lead to increased activity of the
GCs.
11,12 In 2006 Bruch-Graher and colleagues
argued a lymphatic origin of the angiomatosis
leading  to  lesion  formation.
5,10 A  publication
written by Hagendoorn et al. emphasized the
evidence supporting lymphatic vasculature as
the  tissue  of  origin  for  Gorham-Stout  syn-
drome tumors. Hagendoorn et al. found that
the majority of endothelial cells in the lesions
expressed  a  surface  protein  indicative  of
lymph  atics,  lymphatic  vascular  endothelial
hyaluronan receptor-1 (LYVE-1).
4,13 In concord -
ance  with  previously  reported  findings,
Hagendoorn et al. identified high circulating
levels of VEGF and PDGF subtypes.
11,13
The  majority  of  cases  reported  show
spontan  eous  resolution  of  disease  for
unknown reasons.
4,14,15 However, rare cases of
chronic  recurrent  angiomatosis  have  been
reported, many ultimately resulting in death.
Chylothorax and spinal cord compression are
two of the more severe examples of complica-
tions  resulting  from  chronic  disease.
Chylothorax results from occlusion of the large
lymphatic  vessels  in  the  thorax  and  in  turn
leads to fluid collection.
5,10,11 Osseous degener  -
ation of the vertebrae leads to skeletal frame-
work  compromisation  and  spinal  cord  com-
pression.  Prompt  therapeutic  intervention  is
recommended with evidence of lymphatic or
vertebral invasion.
1,7,10,16,17
There is no known cure for Gorham-Stout
syndrome and as such treatment depends on
patient  specific  variables.  Historically,  local
control was the primary therapeutic goal for
recurrent  disease.  Classically,  local  disease
was managed with a combination of surgical
resection  or  radiation  therapy.
10,18-21 Investi  -
gation of the literature indicates radiotherapy
to be the best option to halt disease progres-
sion,  with  reported  results  showing  foci  of
bone  regrowth.
7,10,18-21 Investigation  into  the
pathophysiology  behind  Gorham-Stout  syn-
drome has resulted in an evolution in treat-
ment options targeting proposed pathophysio-
logical pathways. For example, bisphosphonate
therapy has been shown to decrease osteolytic
activity,
22 and as such may play a role in limit-
ing  the  osteolytic  breakdown  of  bone  in
Gorham-Stout  syndrome.  In  addition,  mono-
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clonal  antibodies  targeting  specific  vascular
growth factors currently are being investigated
to  target  the  receptors  promoting  angiogen  -
esis.
4,23 In  theory,  these  newer  therapeutic
options show promise, but for the most part
are unproven and need further investigation.
Past  pharmaceutical  treatment  of  Gorham-
Stout syndrome often utilized a combination of
multiple  medications.  No  evidence-based 
pharmaceutical treatment protocols were dis-
covered  during  the  literature  review,  but  in
general an approach utilizing different agents
was  encountered.  Examples  of  medications
used are: vitamin D, calcium, adrenal extracts,
parathyroid hormone, bisphosphonates, a-2b
interferon, and androgens.
4,5,24
The side effects of radiotherapy in treating
Gorham-Stout syndrome are similar to the side
effects seen with any radiation therapy (skin
hyperpigmentation  and  fatigue).  However,
pneumonitis,  fibrosis,  and  secondary  malig-
nancy are complications that need to be con-
sidered  on  a  per-patient  basis.  As  with  any
therapeutic intervention a patient discussion
should  be  conducted  to  balance  risks  and
potential  benefits  of  therapy.  We  present  a
patient with a multi-year history of progressive
Gorham-Stout  syndrome  characterized  by
recurrent  angiomatosis  involving  the  skin,
skeletal system, liver, mediastinum, and chest
wall. Over her disease course the patient was
treated with multiple surgical resections and
radiation treatments with the goal of pain pal-
liation. Our patient’s disease was progressive
and protracted, leading to a life of recurrent
tumor  formation,  chronic  pain,  pathological
fractures, and ultimately death.
Case Report
The patient initially presented as a 37-year-
old African American woman with a history of
recurrent  “hemangiomas”  of  the  right  chest
wall, right shoulder, and right arm. Since child-
hood she had undergone multiple surgical pro-
cedures as treatment for the lesions. Biopsies
of the lesions were done prior to presentation
and were classified as hemangiomas. Initially,
the complaint was chronic intermittent pain in
her right upper extremity. Laboratory testing
conducted at initial presentation did not indi-
cate  the  presence  of  a  primary  metabolic  or
infectious disease process. Imaging of the right
upper  extremity  showed  multiple  phleboliths
and  osteolytic  changes  of  the  distal  ulna.
Thoracic  spine  X-rays  illustrated  progressive
dextroscoliosis and deformation of the posteri-
or second to fourth right ribs. Physical exami-
nation showed multiple papules, nodules, and
tumors  scattered  throughout  the  right  arm,
right shoulder, and right chest wall. The mass-
es were described as flesh-blue in coloration
and their associated mass effect led to hyper-
trophy and deformation of the right thorax and
upper extremity. Also noted in a distribution
similar  to  the  masses  were  mul  tiple  scars
reflecting the previous surgical procedures. In
conjunction  with  the  pain  that  made  up  the
chief complaint, our patient described limited
motion in all right upper extremity joints. With
the exception of the right upper extremity and
chest wall, the physical examination was with-
out significant findings. Other history of note,
at the age of 34 years our patient experienced a
spontaneous fracture of her right arm and was
treated with reduction and fixation utilizing a
metal plate and screws.
The  patient  was  given  the  diagnosis  of
Gorham-Stout syndrome and was referred for
radiation treatment. Initial radiation was tar-
geted to the right arm in an effort to treat the
pain  owing  to  the  mass  effect  of  the  hem  -
angiomas. The radiation therapy was shown to
be effective at reducing the size of the tumors
and relieving her pain. Because of the lack of
definitive  treatment  for  Gorham-Stout  syn-
drome, management of the patient’s pain guid-
ed therapeutic interventions. In addition to the
radiotherapy  treatments,  the  pain  was  man-
aged  pharmacologically  with  a  spectrum  of
pharmacologic  agents  that  ranged  from
ibuprofen to pethidine.
As the disease progressed tumor formation
was shown to occur at other sites throughout
our patient’s body. For example, one year after
initial  presentation,  thoracic  involvement  of
the tumors resulted in the formation of mul  -
tiple blebs and severe chest pain. At the age of
39 years magnetic resonance imaging (MRI) of
the chest showed soft tissue densities consist  -
ent  with  hemangiomas  in  the  mediastinum,
anterior  to  the  descending  thoracic  aorta.
Avascular necrosis of the left femoral medial
and lateral condyles was diagnosed after our
patient complained of progressive knee pain at
the age of 43 years. The onset of severe pro-
gressive abdominal pain led to an abdominal
MRI  that  showed  hepatic  involvement  of
Gorham-Stout  syndrome.  Over  the  course  of
nearly 20 years our patient underwent approxi-
mately  15  separate  radiation  therapy  treat-
ments  to  alleviate  pain  secondary  to  hem  -
angioma formation. Both electron and photon
particle radiation therapeutic techniques were
utilized as part of her treatment. The choice of
dose given or particle subtype was guided by
the  specific  location  of  the  current  disease.
Unfortunately our patient was unable to avoid
further pathological fractures when, at the age
of 46 years, a full body X-Ray showed fractures
of the seventh to ninth right ribs. 
An autopsy was performed on 7/21/2009 but
was limited to the right thorax and right arm
(the forearm was not included). Relative to the
left hemisphere of the patient, external examin  -
ation  indicated  atrophic  changes  in  both  the
right arm and the right thorax. Gross examinat  -
ion of the thorax showed hemi-diaphragmatic
elevation and right fibrothorax. Congruent with
external  findings  the  musculature  and  bony
framework of the right upper arm and thorax
were atrophied. The humerus was thin and tri-
angular-shaped on cross section, with a thin rim
of cortical bone. Cystic changes within the tra-
becular bone were observed in the head of the
humerus. Microscopy of the right humerus fol-
lowing  formalin  fixation  and  decalcification
showed  a  slight  prominence  of  blood  vessels
within the cortical bone, consistent with but not
diagnostic of Gorham-Stout syndrome.
Discussion
Gorham-Stout  syndrome  is  an  extremely
rare disease, with slightly more than 200 cases
having been reported since the disease was
first described in 1955. The patient presented
had a chronic progressive disease course with
soft  tissue/cutaneous  involvement;  both  fac-
tors being rare variants of the already rare dis-
ease.
5,15 As discussed earlier, the treatment for
Gorham-Stout  syndrome  mainly  targets  the
patient’s  symptoms,  especially  in  consider  -
ation of the high rate of spontaneous remis-
sion.
1,8,15 Treatment options utilized in the past
consisted of surgical resection and radiother  -
apy.
14-16,18-21,25 Our  patient  presented  with  a
chronic history of recurrent tumors and surgi-
cal  interventions.  A  review  of  the  literature
indicated  radiosensitivity  of  Gorham-Stout
syndrome specific cells, and radiation therapy
had  been  reported  with  mixed  results  as  a
treatment  of  recurrent  Gorham-Stout  syn-
drome.
14,16,18-21,25 Our  treatment  followed  an
aggressive yet controlled model similar to that
of Dunbar and his colleagues. Dunbar found
success  in  treating  patients  with  moderate
doses of EBR (40-45 Gy in 1.8-2 Gy fractions).
26
In a review of 22 cases Dunbar found 64% suc-
cess (14/22).
26 Another review of 18 cases by
Choma had 11 patients achieving local control
with five showing signs of reossification.
14 In
general, radiotherapy is a valid alternative for
patients  who  have  found  poor  success  with
surgery, who are not good surgical candidates
or simply want to avoid the anesthesia and the
protracted recovery time associated with surgi-
cal procedures.
Owing to the lack of optimal symptom con-
trol  with  previous  treatment  modalities  the
decision was made to proceed with radiation
therapy in our patient. She received 20 differ-
ent prescriptions of radiotherapy over a 15-
year time period. Doses ranged from 15 Gy in
10 fractions of 1.5 Gy to 40 Gy in 20 fractions
of 2 Gy. Because of the external location of
many of her masses (cutaneous, superficial
bones in the hand, etc.), electron beam radio-
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therapy was also used in our patient. There
was  no  therapeutic  difference  noted  in  the
effectiveness between the photon or electron
beams. Similar to the photon fraction doses,
the prescribed electron fractions ranged from
1.5-2.0 Gy per fraction. As expected, the mass-
es targeted by radiotherapy responded well to
the  treatments  and  the  patient’s  symptoms
were managed adequately. However, she expe-
rienced multiple recurrences at both local and
distant sites and as such she never found full
relief  of  her  symptoms.  The  case  presented
illustrates  important  points  associated  with
rare  diseases  such  as  Gorham-Stout  syn-
drome, and which present many obstacles dur-
ing clinical investigation. For example, there
is difficulty accumulating a population suffi-
ciently large enough to conduct clinical trials
to investigate treatment options. Lacking that
ability  to  test  hypotheses  in  valid  evidence-
based trials leads to treatment guided by con-
sensus medicine and pathophysiological “best
guesses.” Gorham-Stout syndrome is a perfect
example; newer options for curative therapy
are  based  on  targeting  the  proposed  patho-
physiological  angiogenic  growth  factors.
These  newer  techniques  offer  theoretical
promise but are largely unproven. Evidence-
based randomized trials need to be conducted
to identify the benefit or lack thereof. Another
obstacle in the investigation of treatment for
Gorham-Stout syndrome is the relatively high
spontaneous remission rate. Disease resolu-
tion, whether in clinical studies or practice,
cannot be definitively quantified as a treat-
ment response because of such spontaneous
remission.  In  addition,  there  is  still  much
work to be done in elucidating the etiological
process  and  treatment  options  for  Gorham-
Stout syndrome. 
Our  patient  presented  with  a  chronic,
recurrent,  and  progressive  disease  course.
She was highly symptomatic (pain) and found
little  relief  from  surgery  and  analgesics.  To
that end, radiation therapy was utilized to con-
trol  the  tumors  locally  and  to  alleviate  the
associated pain. To the benefit of our patient,
the radiation proved to be successful and vast-
ly improved her quality of life. Yet, owing to its
solely palliative role, the radiation did not cure
her disease. This case illustrates the thera  -
peutic effectiveness of radiotherapy for local
control/bone regrowth as well as the need for
further investigation into curative treatment
options for Gorham-Stout syndrome.
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